+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease

RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease

Current Molecular Medicine 7(8): 735-742

This review focuses on the current findings regarding interaction between amyloid beta peptide (Abeta) and receptor for advanced glycation endproducts (RAGE) and its roles in the pathogenesis of Alzheimer's disease (AD). As a ubiquitously expressed cell surface receptor, RAGE mediates the effects of Abeta on microglia, blood-brain barrier (BBB) and neurons through activating different signaling pathways. Data from autopsy brain tissues, in vitro cell cultures and transgenic mouse models suggest that Abeta-RAGE interaction exaggerates neuronal stress, accumulation of Abeta, impaired learning memory, and neuroinflammation. Blockade of RAGE protects against Abeta-mediated cellular perturbation. These findings may have an important therapeutic implication for neurodegenerative disorders relevant to AD.

(PDF emailed within 1 workday: $29.90)

Accession: 055333035

Download citation: RISBibTeXText

PMID: 18331231

Related references

RAGE: A potential target for a mediated cellular perturbation in Alzheimer's disease. 2007

RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease. Frontiers in Bioscience 4: 240-250, 2013

RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?. Journal of Alzheimer's Disease 16(4): 833-843, 2009

Role of RAGE in Abeta - dependent neuronal perturbation studies in RAGE null mice. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 945 24, 2003

Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. Journal of Neuroscience 26(18): 4717-4728, 2006

ABAD: a potential therapeutic target for Abeta-induced mitochondrial dysfunction in Alzheimer's disease. Mini Reviews in Medicinal Chemistry 9(8): 1002-1008, 2009

RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease. Restorative Neurology and Neuroscience 12(2-3): 167-173, 2003

RAGE and Abeta immunoglobulins: relation to Alzheimer's disease-related cognitive function. Journal of the International Neuropsychological Society 16(4): 672-678, 2010

Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Advanced Drug Delivery Reviews 54(12): 1603-1613, 2002

RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. Faseb Journal 23(8): 2639-2649, 2009

RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. Embo Journal 23(20): 4096-4105, 2004

RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. Faseb Journal 24(4): 1043-1055, 2010

Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Medicine 3(1): 29-39, 2003

Is RAGE still a therapeutic target for Alzheimer's disease?. Future Medicinal Chemistry 4(7): 915-925, 2012

Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Molecular and Cellular Neurosciences 15(2): 183-198, 2000